ClinicalTrials.gg
RecruitingNCT07517042Updated Nov 12, 2026

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

An interventional study of Mazdutide and Intensive Lifestyle Intervention in Obesity and Weight Control, sponsored by Shanghai Zhongshan Hospital. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 12, 2026Interventions changed10 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Planned enrollment
5th of 22
420 · median 187
Started
2026
with 7 others
No phase
4 of 22
4 open now
Primary completion
2028-12
later than 11 of 13 live
Registered
16th of 22
by date
Lead sponsor
1 of 22
Shanghai Zhongshan Hospital

Among the 22 studies testing mazdutide in Obesity, this one is the 5th largest by planned enrollment, is one of 8 that started in 2026, is one of 4 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 16th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance.

This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.

03

Conditions studied

  • Obesity
  • Weight Control

Keywords

  • obesity
  • GLP-1 RA
  • Exercise
  • Nutrition
  • Sustained weight Control
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men or women aged 18 years or older;
  • Simple obesity, defined as a (BMI) of 28.0-45.0 kg/m²;
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • Active pulmonary tuberculosis, malignant tumors, (HIV) infection, or other serious infectious or systemic diseases;
  • Severe hepatic impairment ( [AST] or alanine aminotransferase [ALT] >3 times the ), severe renal impairment, or end-stage renal disease (estimated [eGFR] \<30 mL/min/1.73 m²);
  • Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months;
  • Severe gastrointestinal diseases, or a history of gastrointestinal resection surgery within the past year;
  • Acute or chronic pancreatitis, gallbladder disease, or pancreatic injury;
  • Obesity secondary to other causes, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, or acromegaly; drug-induced obesity, such as obesity related to the use of antipsychotic agents or ;
  • Current smoker or habitual smoking within the past 3 months;
  • Current use of other weight-loss medications or a history of bariatric surgery;
  • Previously diagnosed diabetes mellitus or current use of glucose-lowering medications;
  • Pregnant or breastfeeding women, or women planning pregnancy during the study period;
  • Inability to complete a 2-year follow-up due to health conditions, relocation, or other reasons;
  • Any other condition deemed by the investigator to make the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Mazdutide Placebo plus Intensive Lifestyle Intervention

    After 16-week intensive treatment with mazdutide, participants are randomized into four different arms. In this arm, participants receive mazdutide placebo once weekly plus intensive lifestyle intervention for 52 weeks during the weight maintenance period.

    Behavioral: Intensive Lifestyle Intervention · Drug: Mazdutide Placebo

  • Experimental
    Mazdutide plus Usual Lifestyle Counseling

    After 16-week intensive treatment with mazdutide, participants are randomized into four different arms. In this arm, participants receive mazdutide 3.0 mg once weekly plus usual lifestyle counseling for 52 weeks during the weight maintenance period.

    Drug: Mazdutide · Behavioral: Usual Lifestyle Counseling

  • Experimental
    Mazdutide plus Intensive Lifestyle Intervention

    After 16-week intensive treatment with mazdutide, participants are randomized into four different arms. In this arm, participants receive mazdutide 3.0 mg once weekly plus intensive lifestyle intervention for 52 weeks during the weight maintenance period.

    Drug: Mazdutide · Behavioral: Intensive Lifestyle Intervention

  • Experimental
    Mazdutide Placebo plus Usual Lifestyle Counseling

    After 16-week intensive treatment with mazdutide, participants are randomized into four different arms. In this arm, participants receive mazdutide placebo once weekly plus usual lifestyle counseling for 52 weeks during the weight maintenance period.

    Drug: Mazdutide Placebo · Behavioral: Usual Lifestyle Counseling

Interventions

  • Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.

  • BehavioralIntensive Lifestyle Intervention

    Participants receive a structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.

  • DrugMazdutide Placebo

    Mazdutide placebo is administered subcutaneously once weekly for 52 weeks during the weight maintenance period.

  • BehavioralUsual Lifestyle Counseling

    Participants receive general health education and non-intensive lifestyle advice on healthy eating, physical activity, and weight management for 52 weeks during the weight maintenance period.

06

What researchers measure

Primary outcomes

  1. Percentage change of body weight

    Time frame: From randomization to Week 52

Secondary outcomes

  1. Change in body mass index (BMI)

    Time frame: From randomization to Week 52

  2. Change in waist circumference

    Time frame: From randomization to Week 52

  3. Change in total body fat

    Time frame: From randomization to Week 52

  4. Change in abdominal visceral fat area

    Abdominal visceral fat area is quantified by CT scan

    Time frame: From randomization to Week 52

  5. Change in hepatic fat content

    Hepatic fat content is quantified by controlled attenuation parameter (CAP), measured by Fibroscan.

    Time frame: From randomization to Week 52

  6. Change in blood pressure

    Time frame: From randomization to Week 52

  7. Change in serum lipid profile

    Time frame: From randomization to Week 52

  8. Changes in blood glucose

    Time frame: From randomization to Week 52

  9. Changes in insulin sensitivity

    Insulin sensitivity is assessed by HOMA-IR index

    Time frame: From randomization to Week 52

  10. Changes in pancreatic β-cell function

    Pancreatic β-cell function is assessed by HOMA-β index

    Time frame: From randomization to Week 52

  11. Change in pulse wave velocity (PWV)

    Time frame: From randomization to Week 52

  12. Quality of sleep measured by the Pittsburgh sleep quality index (PSQI)

    Time frame: From randomization to Week 52

  13. Quality of life measured by the 12-item Short-Form Health Survey Questionnaire (SF-12)

    Time frame: From randomization to Week 52

07

Study locations

21 of 21 sites recruiting
  • Fujian Provincial Hospital, Affiliated to Fuzhou University
    Fuzhou, Fujian 350000, China
    Recruiting
    • Junping When, MD, PhD · Contactjunpingwen@163.com · 86-0591-88216000
    • Junping When, MD, PhD · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
    Recruiting
    • Xin Zheng, MD · Contactzx2001528@163.com · 86-0592-2132222
    • Changqin Liu, MD · Principal investigator
  • Zhongshan Hospital (Xiamen), Fudan University
    Xiamen, Fujia 361000, China
    Recruiting
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550004, China
    Recruiting
    • Miao Zhang, MD, PhD · Contactzhangmiao@gmc.edu.cn · +86-851-86855119
    • Miao Zhang, MD, PhD · Principal investigator
  • The Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
    Recruiting
    • Xin Liao, MD, PhD · Contactliaoxin8618@163.com · +86-851-28609600
    • Xin Liao, MD, PhD · Principal investigator
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430000, China
    Recruiting
  • The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University
    Suzhou, Jiangsu 215000, China
    Recruiting
    • Zhimin Ma, MD · Contactmazhimin01@sina.com · 86-0512-69584800
    • Zhimin Ma, MD · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Jianping Liu, MD, PhD · Contactliujpnfm@163.com · +86-791-86297662
    • Jianping Liu, MD, PhD · Principal investigator
  • Huadong Hospital, Fudan University
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
    • Bin Lu, PhD · Contactlubinfd@126.com · 86-021-62483180
    • Bin Lu, PhD · Principal investigator
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
    • Jing Ma, PhD · Contactcherry1996@live.cn · 86-021-58752345
    • Jing Ma, PhD · Principal investigator
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
    • Yufan Wang, MD, PhD · Contactyyffwang@sina.com · +86-21-63240090
    • Yufan Wang, MD, PhD · Principal investigator
  • Shanghai Tenth People's Hospital, School of Medicine, Tongji University
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
  • Tongren Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
    • Shan Huang, MD, PhD · Contacths1147@126.com · +8602152039999
    • Shan Huang, MD, PhD · Principal investigator
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi 030012, China
    Recruiting
    • Jie Qin, MD, PhD · Contactbxl5cnfmsys@163.com · +86-351-4960130
    • Jie Qin, MD, PhD · Principal investigator
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
    Recruiting
    • Shiwei Liu, MD, PhD · Contactliushiwei@sxbqeh.com.cn · +86-351-8368114
    • Shiwei Liu, MD, PhD · Principal investigator
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
    Recruiting
    • Yong Xu, MD · Contactxywyll@aliyun.com · 86-0830-3165233
    • Yong Xu, MD · Principal investigator
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Chao Zheng, MD, PhD · Contactwallbb_1022@163.com · +86-571-87783777
    • Chao Zheng, MD, PhD · Principal investigator
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Xiaohong Wu, MD · Contactdrxhwu@163.com · 86-0571-85893111
    • Xiaohong Wu, MD · Principal investigator
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Xiaomu Li, MD, PhD · Contactli.xiaomu@zju.edu.cn · +86-571-87236114
    • Xiaomu Li, MD, PhD · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
    • Hong Zhu, MD · Contactzhuhong@wmn.edu.cn · 86-0577-55579999
    • Hong Zhu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol

Time frame: After publication.

Access criteria: IPD and supporting information will be avaible to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 30 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 8, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 2 sites removed
Show 10 added (10 China)
  • Zhongshan Hospital (Xiamen), Fudan University · Xiamen, China
  • The Affiliated Hospital of Guizhou Medical University · Guiyang, China
  • The Affiliated Hospital of Zunyi Medical University · Zunyi, China
  • The Second Affiliated Hospital of Nanchang University · Nanchang, China
  • Shanghai General Hospital · Shanghai, China
  • Tongren Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Shanxi Provincial People's Hospital · Taiyuan, China
  • Shanxi Bethune Hospital · Taiyuan, China
  • The Second Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
Show 2 removed
  • The Second Affiliated Hospital of Chongqing Medical University · Chongqing, China
  • Nanjing First Hospital, Nanjing Medical University · Nanjing, China
Nov 12, 2026
Interventions
Added Drug: Mazdutide Placebo·Behavioral: Usual Lifestyle Counseling. Arm changed Placebo plus Intensive Lifestyle Intervention→Mazdutide Placebo plus Intensive Lifestyle Intervention. Arms added: Mazdutide plus Usual Lifestyle Counseling·Mazdutide Placebo plus Usual Lifestyle Counseling; arms removed: Mazdutide·Standard Health Education (Control)
Oct 22, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Fujian Provincial Hospital, Affiliated to Fuzhou University · Fuzhou, ChinaContact c•••@163.com · •••6000→j•••@163.com · •••6000Contact person changed (no phone or email listed)
  • Shanghai Tenth People's Hospital, School of Medicine, Tongji University · Shanghai, ChinaContact q•••@hotmail.com · •••3680→g•••@hotmail.com · •••3680Contact person changed (no phone or email listed)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    10 sites added, 2 sites removed
    Show 10 added (10 China)
    • Zhongshan Hospital (Xiamen), Fudan University · Xiamen, China
    • The Affiliated Hospital of Guizhou Medical University · Guiyang, China
    • The Affiliated Hospital of Zunyi Medical University · Zunyi, China
    • The Second Affiliated Hospital of Nanchang University · Nanchang, China
    • Shanghai General Hospital · Shanghai, China
    • Tongren Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Shanxi Provincial People's Hospital · Taiyuan, China
    • Shanxi Bethune Hospital · Taiyuan, China
    • The Second Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
    • The First Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
    Show 2 removed
    • The Second Affiliated Hospital of Chongqing Medical University · Chongqing, China
    • Nanjing First Hospital, Nanjing Medical University · Nanjing, China
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Fujian Provincial Hospital, Affiliated to Fuzhou University · Fuzhou, ChinaContact c•••@163.com · •••6000→j•••@163.com · •••6000Contact person changed (no phone or email listed)
    • Shanghai Tenth People's Hospital, School of Medicine, Tongji University · Shanghai, ChinaContact q•••@hotmail.com · •••3680→g•••@hotmail.com · •••3680Contact person changed (no phone or email listed)
  2. Oct 22, 2026
    Interventions Added Drug: Mazdutide Placebo·Behavioral: Usual Lifestyle Counseling. Arm changed Placebo plus Intensive Lifestyle Intervention→Mazdutide Placebo plus Intensive Lifestyle Intervention. Arms added: Mazdutide plus Usual Lifestyle Counseling·Mazdutide Placebo plus Usual Lifestyle Counseling; arms removed: Mazdutide·Standard Health Education (Control)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07517042
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Jun 10, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

JINGJING JIANG, MD, PhD
Contact
jiang.jingjing@zs-hospital.sh.cn
86-21-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion